

Fellows' Circle 2021

As part of the 50th anniversary celebrations, we will be launching the Fellows' Circle 2021, to recognise those who include WHR as a beneficiary in their will or otherwise contribute to funding the John Vane Chair. If you are interested in becoming a Fellow, please get in touch.

If you wish to discuss other ways of helping WHR, or you would simply like further information about our work, we would be delighted to hear from you.



William Harvey Research Foundation
John Vane Science Centre
Charterhouse Square
London
EC1M 6BQ

development@whrf.org.uk
www.whrf.org.uk


Registered in England - Registration No. 2472965
Charity Registration 803012

 **Queen Mary**
University of London
Barts & The London

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

 Registered with
**FUNDRAISING
REGULATOR**

WHRF WILLIAM HARVEY
RESEARCH FOUNDATION



John Vane Chair in Therapeutic Innovation

Sir John Vane Nobel laureate

Pharmacological discoveries

Many who take medicines for high blood pressure, pain, chronic inflammation or cardiovascular diseases owe a debt to John Vane. His research identified how aspirin works, benefitting over 100 million people who suffer heart attacks, arthritis, and other cardiovascular and inflammatory conditions; the therapeutic use of ACE inhibitors, taken by over 10 million people to lower high blood pressure; and the role of prostacyclin, which helps many thousands with pulmonary artery hypertension.

Sir John Vane awarded the Nobel Prize in Physiology or Medicine in 1982 for discoveries concerning prostaglandins and related biologically active substances.

William Harvey Research

In 1986, John Vane established the William Harvey Research Institute at St Bartholomew's Hospital Medical College. Based in Charterhouse Square in the City of London, WHR is now one of the world's leading pharmacological research centres, with over 500 scientists from many countries.

Therapeutic Innovation

John Vane's work on specialist drug development and fundamental pharmacological research continues at WHR today. To drive drug discovery to address urgent unmet medical need and to build on his legacy, WHR wants to establish the John Vane Chair in Therapeutic Innovation

John Vane Chair

It is intended to appoint the first incumbent by the end of 2021, to mark the 50th anniversary of John Vane's paper explaining aspirin's mechanism of action. The appointee will be a researcher of international standing in cardiovascular and/or inflammatory disease, committed to novel therapeutic approaches, either by discovering drugs with new mechanisms of action, or by re-purposing established drugs for different clinical conditions (a strategy that has already been successful at WHR).

The initial appointment will be followed by further fundraising initiatives to support the Chair with equipment, staff, designated laboratories and research grants, thus creating a high-quality research group that will have a significant impact on therapeutic innovation.

Funding status

Donations and commitments have already been received, including pledges of legacies, corporate guarantees, offers of matched funding for subsequent donations, and contributions from charities.

Our fundraising campaign aims to raise £1.5 million over the next two years for the John Vane Chair; it will culminate in 2021 with a conference to celebrate the 50th anniversary of John Vane's seminal paper on aspirin.



WHR is now one of the world's leading pharmacological research centres, with over **500 SCIENTISTS** from many countries.



Aiming to raise **£1.5 MILLION** over the next two years.

